Difference between revisions of "Part:BBa K3924015"
Line 3: | Line 3: | ||
<partinfo>BBa_K3924015 short</partinfo> | <partinfo>BBa_K3924015 short</partinfo> | ||
− | + | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
Line 12: | Line 12: | ||
<partinfo>BBa_K3924015 SequenceAndFeatures</partinfo> | <partinfo>BBa_K3924015 SequenceAndFeatures</partinfo> | ||
+ | ==Profile== | ||
+ | Name: STⅡ<br/> | ||
+ | Base Pairs: 72<br/> | ||
+ | Origin: <i>Escherichia coli</i><br/> | ||
+ | Properties: Signal peptide of <i>Escherichia coli</i> heat-stable enterotoxin II<br/> | ||
+ | ==Usage and Biology== | ||
+ | In order to heal the intestinal tract damage, one of notable symptoms of IBD, we adopted a special therapy expressing the therapeutic proteins controllably by <i>E.coli Nissle 1917</i> (EcN) in situ. The design is based on a ternary system: sensor - secretion peptide - therapeutic proteins.<br/> | ||
+ | [[Image:General design of the treatment ternary system.png|center|600px|thumb|'''Figure 1: General design of the treatment ternary system''']] | ||
+ | STⅡ is one of candidate secretion peptides we screened out, which is a most essential element that help our therapeutic protein secrete outside the engineered bacteria and diffuse inside the patient's intestinal tract. It is a signal peptide of <i>Escherichia coli</i> heat-stable enterotoxin II[6]. The sequence is mainly based on literature we had reviewed and modified by our condon preference system.<br/> | ||
+ | ==Design and Construction== | ||
+ | According to literature research we chose 7 candidate secretion peptides and did codon analysis with our own software tool.<br/> | ||
+ | Table 1. List of candidate therapeutic proteins | ||
+ | <table border="1"> | ||
+ | <tr> | ||
+ | <th>Part Name</th> | ||
+ | <th>Element Name</th> | ||
+ | <th>Origin</th> | ||
+ | <th>Reference</th> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>BBa_K3924010</td> | ||
+ | <td>DsbA</td> | ||
+ | <td><i>E. coli</i> periplasmic space</td> | ||
+ | <td>[1]</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>BBa_K3924011</td> | ||
+ | <td>CsgA</td> | ||
+ | <td><i>E. coli</i> biofilm matrix</td> | ||
+ | <td>[2]</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>BBa_K3924012</td> | ||
+ | <td>OmpA</td> | ||
+ | <td><i>E. coli</i> outer membrane</td> | ||
+ | <td>[3]</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>BBa_K3924013</td> | ||
+ | <td>PelB</td> | ||
+ | <td><i>Erwinia carotovora</i> periplasmic space</td> | ||
+ | <td>[4]</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>BBa_K3924014</td> | ||
+ | <td>PhoA</td> | ||
+ | <td><i>E. coli</i> periplasmic space</td> | ||
+ | <td>[5]</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>BBa_K3924015</td> | ||
+ | <td>STⅡ</td> | ||
+ | <td><i>E. coli</i> extracellular peptide toxin</td> | ||
+ | <td>[6]</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td>BBa_K3924016</td> | ||
+ | <td>TorA</td> | ||
+ | <td><i>E. coli</i> periplasmic space</td> | ||
+ | <td>[7]</td> | ||
+ | </tr> | ||
+ | </table> | ||
+ | After getting the codon-optimized sequence for <i>E. coli</i>, we synthesized the sequence by company, and linked them to a GFP element by using HiFi Assembly.<br/> | ||
+ | ==Functional Verification== | ||
+ | [[Image:Secretion peptide flowchart.png|center|600px|thumb|'''Figure 2: Secretion peptide flowchart''']] | ||
+ | The functional verification of secretion peptides was conducted by checking the fluorescence of the bacteria supernatant after centrifuging at 8000 rpm for 1 minute. The fluorescence is measured by microplate reader. The results are shown in Figure 3.<br/> | ||
+ | [[Image:Fluorescence intensity.png|center|600px|thumb|'''Figure 3: Fluorescence intensity''']] | ||
+ | With RGP-GFP group (RGP is the plasmid backbone in our design) as a negative control, which doesn’t have any secretion peptide to diffuse GFP out of the protein, RGP-STⅡ-GFP, however, does not show a significant difference. The fluorescence is slightly higher, but maybe due to the volatile lab environment, the significance cannot be shown. Nevertheless, we evaluate this part as a success..<br/> | ||
+ | ==Reference== | ||
+ | [1] Zhou Y Z, Liu P, Gan Y T, et al.Enhancing full-length antibody production by signal peptide engineering.Microbial Cell Factories, 2016,15(1):1-11.<br/> | ||
+ | [2]Van Gerven, N., Klein, R. D., Hultgren, S. J., & Remaut, H. (2015). Bacterial amyloid formation: structural insights into curli biogensis. Trends in microbiology, 23(11), 693–706.<br/> | ||
+ | [3]Zhao F K, Song Q Z, Wang B B, et al.Secretion of the recombination α-amylase in <i>Escherichia coli</i> and purification by the gram-positive enhancer matrix (GEM) particlesInternational Journal of Biological Macromolecules, 2019,123:91-96.<br/> | ||
+ | [4]Sriwidodo S, Subroto T, Maksum I, et al.Optimization of secreted recombinant human epidermal growth factor production using pectate lyase B from <i>Escherichia coli BL21(DE3)</i> by central composite design and its production in high cell density culture<br/> | ||
+ | [5]Mohajeri A, Abdolalizadeh J, Pilehvar-Soltanahmadi Y, et al.Expression and secretion of endostar protein by <i>Escherichia coli</i>: optimization of culture conditions using the response surface methodology Molecular Biotechnology, 2016,58(10):634-647.<br/> | ||
+ | [6]Lu C, Zhao H, Zou W Y, et al.Secretion expression of recombinate human interferon α-2b by <i>Escherichia coli</i> Journal of Biology, 2011,28(3):58-62.<br/> | ||
+ | [7]Guerrero Montero I, Richards K L, Jawara C, et al.<i>Escherichia coli</i> “TatExpress” strains export several g/L human growth hormone to the periplasm by the Tat pathway Biotechnology and Bioengineering, 2019,116(12):3282-3291.<br/> | ||
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display |
Revision as of 07:55, 21 October 2021
STⅡ
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Profile
Name: STⅡ
Base Pairs: 72
Origin: Escherichia coli
Properties: Signal peptide of Escherichia coli heat-stable enterotoxin II
Usage and Biology
In order to heal the intestinal tract damage, one of notable symptoms of IBD, we adopted a special therapy expressing the therapeutic proteins controllably by E.coli Nissle 1917 (EcN) in situ. The design is based on a ternary system: sensor - secretion peptide - therapeutic proteins.
STⅡ is one of candidate secretion peptides we screened out, which is a most essential element that help our therapeutic protein secrete outside the engineered bacteria and diffuse inside the patient's intestinal tract. It is a signal peptide of Escherichia coli heat-stable enterotoxin II[6]. The sequence is mainly based on literature we had reviewed and modified by our condon preference system.
Design and Construction
According to literature research we chose 7 candidate secretion peptides and did codon analysis with our own software tool.
Table 1. List of candidate therapeutic proteins
Part Name | Element Name | Origin | Reference |
---|---|---|---|
BBa_K3924010 | DsbA | E. coli periplasmic space | [1] |
BBa_K3924011 | CsgA | E. coli biofilm matrix | [2] |
BBa_K3924012 | OmpA | E. coli outer membrane | [3] |
BBa_K3924013 | PelB | Erwinia carotovora periplasmic space | [4] |
BBa_K3924014 | PhoA | E. coli periplasmic space | [5] |
BBa_K3924015 | STⅡ | E. coli extracellular peptide toxin | [6] |
BBa_K3924016 | TorA | E. coli periplasmic space | [7] |
After getting the codon-optimized sequence for E. coli, we synthesized the sequence by company, and linked them to a GFP element by using HiFi Assembly.
Functional Verification
The functional verification of secretion peptides was conducted by checking the fluorescence of the bacteria supernatant after centrifuging at 8000 rpm for 1 minute. The fluorescence is measured by microplate reader. The results are shown in Figure 3.
With RGP-GFP group (RGP is the plasmid backbone in our design) as a negative control, which doesn’t have any secretion peptide to diffuse GFP out of the protein, RGP-STⅡ-GFP, however, does not show a significant difference. The fluorescence is slightly higher, but maybe due to the volatile lab environment, the significance cannot be shown. Nevertheless, we evaluate this part as a success..
Reference
[1] Zhou Y Z, Liu P, Gan Y T, et al.Enhancing full-length antibody production by signal peptide engineering.Microbial Cell Factories, 2016,15(1):1-11.
[2]Van Gerven, N., Klein, R. D., Hultgren, S. J., & Remaut, H. (2015). Bacterial amyloid formation: structural insights into curli biogensis. Trends in microbiology, 23(11), 693–706.
[3]Zhao F K, Song Q Z, Wang B B, et al.Secretion of the recombination α-amylase in Escherichia coli and purification by the gram-positive enhancer matrix (GEM) particlesInternational Journal of Biological Macromolecules, 2019,123:91-96.
[4]Sriwidodo S, Subroto T, Maksum I, et al.Optimization of secreted recombinant human epidermal growth factor production using pectate lyase B from Escherichia coli BL21(DE3) by central composite design and its production in high cell density culture
[5]Mohajeri A, Abdolalizadeh J, Pilehvar-Soltanahmadi Y, et al.Expression and secretion of endostar protein by Escherichia coli: optimization of culture conditions using the response surface methodology Molecular Biotechnology, 2016,58(10):634-647.
[6]Lu C, Zhao H, Zou W Y, et al.Secretion expression of recombinate human interferon α-2b by Escherichia coli Journal of Biology, 2011,28(3):58-62.
[7]Guerrero Montero I, Richards K L, Jawara C, et al.Escherichia coli “TatExpress” strains export several g/L human growth hormone to the periplasm by the Tat pathway Biotechnology and Bioengineering, 2019,116(12):3282-3291.